| CILENGITIDE | Protein | gliosarcoma | Integrin alpha-V/beta-5 antagonist | 1.0 | Terminated | ClinicalTrials |
| CILENGITIDE | Protein | myelodysplastic syndrome | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | glioblastoma multiforme | Integrin alpha-V/beta-5 antagonist | 3.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | anaplastic oligodendroglioma | Integrin alpha-V/beta-5 antagonist | 2.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | non-small cell lung carcinoma | Integrin alpha-V/beta-5 antagonist | 2.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | diffuse intrinsic pontine glioma | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | male breast carcinoma | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | melanoma | Integrin alpha-V/beta-5 antagonist | 2.0 | Terminated | ClinicalTrials |
| CILENGITIDE | Protein | gliosarcoma | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | prostate cancer | Integrin alpha-V/beta-5 antagonist | 2.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | glioblastoma multiforme | Integrin alpha-V/beta-5 antagonist | 2.0 | Terminated | ClinicalTrials |
| CILENGITIDE | Protein | small intestine cancer | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | multiple myeloma | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | gliosarcoma | Integrin alpha-V/beta-5 antagonist | 2.0 | Terminated | ClinicalTrials |
| CILENGITIDE | Protein | leukemia | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | anaplastic oligoastrocytoma | Integrin alpha-V/beta-5 antagonist | 2.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | glioblastoma multiforme | Integrin alpha-V/beta-5 antagonist | 2.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | non-small cell lung carcinoma | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | kidney disease | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | Central Nervous System Neoplasm | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | glioblastoma multiforme | Integrin alpha-V/beta-5 antagonist | 2.0 | Unknown status | ClinicalTrials |
| CILENGITIDE | Protein | cerebral astrocytoma | Integrin alpha-V/beta-5 antagonist | 2.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | glioblastoma multiforme | Integrin alpha-V/beta-5 antagonist | 2.0 | Withdrawn | ClinicalTrials |
| CILENGITIDE | Protein | chronic myeloproliferative disorder | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | neoplasm | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | cerebellar astrocytoma | Integrin alpha-V/beta-5 antagonist | 2.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | central nervous system cancer | Integrin alpha-V/beta-5 antagonist | 2.0 | Terminated | ClinicalTrials |
| CILENGITIDE | Protein | anaplastic astrocytoma | Integrin alpha-V/beta-5 antagonist | 2.0 | Completed | ClinicalTrials |
| CILENGITIDE | Protein | sarcoma | Integrin alpha-V/beta-5 antagonist | 1.0 | Terminated | ClinicalTrials |
| CILENGITIDE | Protein | squamous cell carcinoma | Integrin alpha-V/beta-5 antagonist | 1.0 | Completed | ClinicalTrials |